The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis
Rituximab has been frequently used as a second-line treatment for patients with immune thrombocytopenia (ITP). Recently, several studies have proposed low-dose (100 mg or 100mg/m2 per week for 4 weeks) rituximab instead of the standard dose of 375mg/m2 per week for 4 weeks to treat ITP patients. The...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-08-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2019.1624706 |
| _version_ | 1797684199247839232 |
|---|---|
| author | Yunjie Li Yuye Shi Zhengmei He Qiuni Chen Zhenyou Liu Liang Yu Chunling Wang |
| author_facet | Yunjie Li Yuye Shi Zhengmei He Qiuni Chen Zhenyou Liu Liang Yu Chunling Wang |
| author_sort | Yunjie Li |
| collection | DOAJ |
| description | Rituximab has been frequently used as a second-line treatment for patients with immune thrombocytopenia (ITP). Recently, several studies have proposed low-dose (100 mg or 100mg/m2 per week for 4 weeks) rituximab instead of the standard dose of 375mg/m2 per week for 4 weeks to treat ITP patients. The aim of this review was to systematically evaluate the efficacy and safety of low-dose rituximab for patients with ITP. Pubmed, Web of Science, Cochrane Library and Embase were searched to identify the clinical studies published in full text or abstract that met the predefined inclusion criteria. Efficacy analysis was restricted to the studies enrolling five or more patients. While safety analysis was evaluated based on all the studies reported adverse events. Nine studies (329 patients) were included for effect assessment of low-dose rituximab treatment on the patients with ITP. The pooled overall response rate was 63% (95% CI, 0.54–0.71) while the pooled complete response was 44% (95% CI, 0.33–0.55). Thirty-one patients were reported to experience adverse effects associated with rituximab, among them 30 cases suffered mild to moderate side-effects (grade1-2). Only one patient developed into interstitial pneumonia (grade3). No death was reported. Low-dose rituximab exhibited a satisfactory efficacy and safety profile, indicating that this regimen is a promising therapy for ITP, and should be further investigated through randomized clinical trials with standard-dose rituximab. |
| first_indexed | 2024-03-12T00:27:00Z |
| format | Article |
| id | doaj.art-5478024008f34af98aa0ffd58e96e70a |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-12T00:27:00Z |
| publishDate | 2019-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-5478024008f34af98aa0ffd58e96e70a2023-09-15T10:32:01ZengTaylor & Francis GroupPlatelets0953-71041369-16352019-08-0130669069710.1080/09537104.2019.16247061624706The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysisYunjie Li0Yuye Shi1Zhengmei He2Qiuni Chen3Zhenyou Liu4Liang Yu5Chunling Wang6The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityThe Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityThe Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityThe Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityThe Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityThe Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityThe Affiliated Huaian No.1 People’s Hospital of Nanjing Medical UniversityRituximab has been frequently used as a second-line treatment for patients with immune thrombocytopenia (ITP). Recently, several studies have proposed low-dose (100 mg or 100mg/m2 per week for 4 weeks) rituximab instead of the standard dose of 375mg/m2 per week for 4 weeks to treat ITP patients. The aim of this review was to systematically evaluate the efficacy and safety of low-dose rituximab for patients with ITP. Pubmed, Web of Science, Cochrane Library and Embase were searched to identify the clinical studies published in full text or abstract that met the predefined inclusion criteria. Efficacy analysis was restricted to the studies enrolling five or more patients. While safety analysis was evaluated based on all the studies reported adverse events. Nine studies (329 patients) were included for effect assessment of low-dose rituximab treatment on the patients with ITP. The pooled overall response rate was 63% (95% CI, 0.54–0.71) while the pooled complete response was 44% (95% CI, 0.33–0.55). Thirty-one patients were reported to experience adverse effects associated with rituximab, among them 30 cases suffered mild to moderate side-effects (grade1-2). Only one patient developed into interstitial pneumonia (grade3). No death was reported. Low-dose rituximab exhibited a satisfactory efficacy and safety profile, indicating that this regimen is a promising therapy for ITP, and should be further investigated through randomized clinical trials with standard-dose rituximab.http://dx.doi.org/10.1080/09537104.2019.1624706immune thrombocytopenia·rituximab·low-dose·systematic review·meta-analysis |
| spellingShingle | Yunjie Li Yuye Shi Zhengmei He Qiuni Chen Zhenyou Liu Liang Yu Chunling Wang The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis Platelets immune thrombocytopenia·rituximab·low-dose·systematic review·meta-analysis |
| title | The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis |
| title_full | The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis |
| title_fullStr | The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis |
| title_full_unstemmed | The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis |
| title_short | The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis |
| title_sort | efficacy and safety of low dose rituximab in immune thrombocytopenia a systematic review and meta analysis |
| topic | immune thrombocytopenia·rituximab·low-dose·systematic review·meta-analysis |
| url | http://dx.doi.org/10.1080/09537104.2019.1624706 |
| work_keys_str_mv | AT yunjieli theefficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT yuyeshi theefficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT zhengmeihe theefficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT qiunichen theefficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT zhenyouliu theefficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT liangyu theefficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT chunlingwang theefficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT yunjieli efficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT yuyeshi efficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT zhengmeihe efficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT qiunichen efficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT zhenyouliu efficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT liangyu efficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis AT chunlingwang efficacyandsafetyoflowdoserituximabinimmunethrombocytopeniaasystematicreviewandmetaanalysis |